JOHN LATHAM,BRIAN KOVACEVICH,KATIE OLSON,ANNE ELISABETH CARVALHO JENSEN,BEN DUTZAR,JEFFREY T.L. SMITH,MARK LITTON,RANDALL SCHATZMAN,LEON GARCIA-MARTINEZ
申请号：
MX2012005927
公开号：
MX2012005927A
申请日:
2010.11.24
申请国别(地区):
MX
年份:
2012
代理人:
摘要：
The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.La presente invención se dirige a métodos terapéuticos que usan antagonistas de IL-6 tal como un anticuerpo Ab1 o fragmento de anticuerpo que tiene especificidad de enlace para IL-6 para prevenir o tratar una enfermedad o para mejorar la supervivencia o calidad de vida de un paciente en necesidad de los mismos. En modalidades preferidas estos pacientes comprenderán aquellos que exhiben (o están en riesgo de desarrollar) un nivel de proteína C-reactiva en el suero elevado, nivel de albúmina en el suero reducido, D-dímero elevado u otra(s) proteína(s) relacionada(s) con la
